Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries ProMIS Neurosciences Inc. - Common Shares (NQ: PMN ) 1.250 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Aug 22, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 2 Open 1.250 Bid (Size) 0.5000 (2) Ask (Size) 1.390 (4) Prev. Close 1.250 Today's Range 1.250 - 1.250 52wk Range 0.9500 - 3.100 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News Around $2M Bet On This Health Care Stock? Check Out These 3 Stocks Under $5 Insiders Are Aggressively Buying August 19, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday August 12, 2024 It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today! Via InvestorPlace Performance YTD -10.05% -10.05% 1 Month -40.95% -40.95% 3 Month -25.59% -25.59% 6 Month -35.90% -35.90% 1 Year -31.69% -31.69% More News Read More Why Ainos Shares Are Trading Higher By Around 38%; Here Are 20 Stocks Moving Premarket August 12, 2024 Via Benzinga PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q2 2024 August 08, 2024 Via InvestorPlace ProMIS Neurosciences Announces Second Quarter 2024 Financial Results and Recent Highlights August 08, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces Data on the Pathogenic Role of Toxic Misfolded SOD1 Aggregates in ALS Published in Acta Neuropathologica and Open Biology August 06, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences to Participate in BTIG Virtual Biotechnology Conference 2024 August 01, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Showcases Novel Vaccine Approach for Maximal Targeting of Toxic Amyloid-Beta Oligomers at the 2024 Alzheimer’s Association International Conference July 30, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session July 26, 2024 Via Benzinga ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial July 26, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Announces Up to $122.7 Million Private Placement Financing July 26, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q1 2024 May 15, 2024 Via InvestorPlace ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights May 14, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies April 30, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session April 15, 2024 Via Benzinga Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat Earnings April 15, 2024 Via Benzinga Topics Stocks Exposures US Equities ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS April 09, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences to Present in Upcoming Investor Conferences in April April 04, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire PMN Stock Earnings: ProMIS Neurosciences Beats EPS for Q4 2023 April 01, 2024 Via InvestorPlace ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights April 01, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio March 11, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference February 22, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine January 22, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire ProMIS Neurosciences Issues Letter to Shareholders January 08, 2024 From ProMIS Neurosciences Inc. Via GlobeNewswire Why TransCode Therapeutics Shares Are Trading Lower By Over 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session January 19, 2024 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
